InflaRx (IFRX) EPS (Weighted Average and Diluted) (2016 - 2026)
InflaRx's (IFRX) quarterly EPS (Weighted Average and Diluted) came in at -$0.09 in Q1 2026, up 51.97% year-on-year from -$0.06 in Q1 2025, and down 100.0% quarter-over-quarter from $27426.2 in Q4 2025.
InflaRx (IFRX) EPS (Weighted Average and Diluted) (2016 - 2026) Analysis & Trends
InflaRx has disclosed EPS (Weighted Average and Diluted) across 11 years of filings, most recently posting -$0.09 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.09, up 51.97% year-over-year; the trailing twelve-month figure through Mar 2026 was -$0.09 (up 51.97% YoY), and the FY2025 annual result was -$0.79, up 5.03% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$0.09 for Q1 2026 at InflaRx, down from $27426.2 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $27426.2 in Q4 2025 to a low of -$34084.5 in Q2 2024.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.15 (2023), against an average of -$1510.1.
- Across the five-year window, EPS (Weighted Average and Diluted) sank 23378711.96% in 2024 and surged 3739764.55% in 2025, its largest moves.
- InflaRx's EPS (Weighted Average and Diluted) stood at -$0.17 in 2022, then plunged by 39.72% to -$0.24 in 2023, then jumped by 401.63% to $0.73 in 2024, then soared by 3739764.55% to $27426.2 in 2025, then plunged by 100.0% to -$0.09 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$0.09 (Q1 2026), $27426.2 (Q4 2025), and -$0.12 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 3.06 |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | 0.00 |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -0.61 |
| 10 | InflaRx | 764.68 Mn | 764.68 Mn | 10,877.40 | -0.09 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -0.09 |
| Dec 31, 2025 | 27,426.21 |
| Sep 30, 2025 | -0.12 |
| Jun 30, 2025 | -33,996.14 |
| Mar 31, 2025 | -0.20 |
| Dec 31, 2024 | 0.73 |
| Sep 30, 2024 | -0.22 |
| Jun 30, 2024 | -34,084.46 |
| Mar 31, 2024 | -0.20 |
| Dec 31, 2023 | -0.24 |
| Sep 30, 2023 | -0.14 |
| Jun 30, 2023 | -0.15 |
| Mar 31, 2023 | 10,309.28 |
| Dec 31, 2022 | -0.17 |
| Sep 30, 2022 | 4,673.88 |
| Jun 30, 2022 | -0.02 |
| Mar 31, 2022 | -0.33 |
| Dec 31, 2021 | 3,222.37 |
| Sep 30, 2021 | -0.29 |
| Jun 30, 2021 | -0.32 |